On April 28, 2014, Vision-Sciences, Inc. (NASDAQ:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, announced financial results for the fourth quarter and full year fiscal 2014, ended March 31, 2014. Vision-Sciences, Inc. (NASDAQ:VSCI), shares after opening at $1.04 moved to $1.20 on last trade day and at the end of the day closed at $1.17. Company price to sales ratio in past twelve months was calculated as 3.41 and price to cash ratio as 50.54. Vision-Sciences, Inc. (NASDAQ:VSCI), showed a positive weekly performance of 5.41%.
Biocept Inc (NASDAQ:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, announced the launch of its clinical research services offering. Biocept Inc (NASDAQ:BIOC), shares advanced 13.89% in last trading session and ended the day on $5.40. Biocept Inc (NASDAQ:BIOC), return on equity ratio is recorded as 272.40%.
On May 01, 2014, CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, reported financial results for the 3 months ended March 31, 2014, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR), shares moved up 15.64% in last trading session and was closed at $3.55, while trading in range of $ 3.10 – 3.62. CytRx Corporation (NASDAQ:CYTR), year to date (YTD) performance is -43.38%.
The Medicines Company (Nasdaq:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announced the presentation of new pre-clinical data from ALN-PCSsc, targeting PCSK9 for the treatment of hypercholesterolemia. These data are being presented at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions being held May 1-3 in Toronto, Ontario. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), weekly performance is 3.13%. On last trading day company shares ended up $54.43. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), distance from 50-day simple moving average (SMA50) is -19.59%. Analysts mean target Price for the company is $101.00.